A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-11-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels
and preliminary antitumor activity of BMS-986416 when administered alone and in combination
with Nivolumab in participants with select advanced solid tumors.